Colorectal Cancer
Specialty Channel

Featured Article
True or false: Is anlotinib beneficial in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer?
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
Carboplatin plus paclitaxel should be considered as a new standard of care for advanced anal cancer, results from an international phase 2 trial suggest.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.

News

Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.

Interactive Features

True or false: Is anlotinib beneficial in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer?
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
Stay in the know.
OncNet Newsletter